Baidu
map

J Glaucoma.:纤维血管生长引起Ahmed Valve上游阻塞的手术解决方法!

2017-09-03 cuiguizhong MedSci原创

葡萄牙圣玛丽亚医院眼科系的Medeiros Pinto J近日在J Glaucoma杂志上发表了一篇文章,他们介绍了一例年轻的患者,在穿透性角膜移植术后患有晚期青光眼和慢性葡萄膜炎,并进行探索实验,成功通过手术方法来治疗纤维血管生长引起Ahmed Valve上游阻塞。

葡萄牙圣玛丽亚医院眼科系的Medeiros Pinto J近日在J Glaucoma杂志上发表了一篇文章,他们介绍了一例年轻的患者,在穿透性角膜移植术后患有晚期青光眼和慢性葡萄膜炎,并进行探索实验,成功通过手术方法来治疗纤维血管生长引起Ahmed Valve上游阻塞。

穿透性角膜移植术后引发的青光眼治疗目前仍具有极大的挑战,可能需要多次手术来控制眼内压(IOP),包括设置青光眼引流植入物来降低眼内压。然而,这些引流植入手术在晚期进行时通常是失败的,主要是因为通常需要进一步手术来消除过度的瘢痕或囊泡。

在这篇文章中,作者介绍了一例年轻的患者,他在穿透性角膜移植术后患有晚期青光眼和慢性葡萄膜炎。他已经进行了2个失败的小梁切片和没有功能的Ahmed 瓣膜手术,在这种最大限度的治疗情况下仍出现眼内压升高的情况。由于没有看到瓣膜覆盖板上的气泡,所以安排了一项探索性的手术修复。房水引流失败的原因被确定为是进入纤维血管向瓣膜板狭缝内生长。他们继续去除这种膜,并确认台盼蓝可以通过,同时使用丝裂霉素C来防止纤维血管向内生长的复发。

结果他们在6个月的随访中发现,板上存在弥漫性泡沫,眼内压值在该患者的目标值内(<16 mm Hg)。研究者的这种探索性工作确定了引流装置出现故障的不寻常原因,并对其改善方法进行了探索,而没有将这些装置拆除。这可以给眼科临床医生带来更多的治疗启示。

原文出处:

Medeiros Pinto, J., N. Pinto Ferreira, and L. Abegao Pinto, Ahmed Valve Upstream Obstruction Caused by Fibrous Ingrowth: Surgical Approach. J Glaucoma, 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804499, encodeId=b980180449999, content=<a href='/topic/show?id=6484e7286bb' target=_blank style='color:#2F92EE;'>#纤维血管生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77286, encryptionId=6484e7286bb, topicName=纤维血管生长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed May 23 08:07:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914184, encodeId=b7791914184f0, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Sep 27 11:07:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796683, encodeId=eeee1e9668332, content=<a href='/topic/show?id=e08d182e056' target=_blank style='color:#2F92EE;'>#valve#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18270, encryptionId=e08d182e056, topicName=valve)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Thu May 24 11:07:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696760, encodeId=35001696e6071, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 03 18:07:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608010, encodeId=fa1f1608010d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 05 02:07:00 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804499, encodeId=b980180449999, content=<a href='/topic/show?id=6484e7286bb' target=_blank style='color:#2F92EE;'>#纤维血管生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77286, encryptionId=6484e7286bb, topicName=纤维血管生长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed May 23 08:07:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914184, encodeId=b7791914184f0, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Sep 27 11:07:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796683, encodeId=eeee1e9668332, content=<a href='/topic/show?id=e08d182e056' target=_blank style='color:#2F92EE;'>#valve#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18270, encryptionId=e08d182e056, topicName=valve)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Thu May 24 11:07:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696760, encodeId=35001696e6071, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 03 18:07:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608010, encodeId=fa1f1608010d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 05 02:07:00 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-27 aliceclz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804499, encodeId=b980180449999, content=<a href='/topic/show?id=6484e7286bb' target=_blank style='color:#2F92EE;'>#纤维血管生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77286, encryptionId=6484e7286bb, topicName=纤维血管生长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed May 23 08:07:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914184, encodeId=b7791914184f0, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Sep 27 11:07:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796683, encodeId=eeee1e9668332, content=<a href='/topic/show?id=e08d182e056' target=_blank style='color:#2F92EE;'>#valve#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18270, encryptionId=e08d182e056, topicName=valve)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Thu May 24 11:07:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696760, encodeId=35001696e6071, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 03 18:07:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608010, encodeId=fa1f1608010d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 05 02:07:00 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804499, encodeId=b980180449999, content=<a href='/topic/show?id=6484e7286bb' target=_blank style='color:#2F92EE;'>#纤维血管生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77286, encryptionId=6484e7286bb, topicName=纤维血管生长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed May 23 08:07:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914184, encodeId=b7791914184f0, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Sep 27 11:07:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796683, encodeId=eeee1e9668332, content=<a href='/topic/show?id=e08d182e056' target=_blank style='color:#2F92EE;'>#valve#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18270, encryptionId=e08d182e056, topicName=valve)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Thu May 24 11:07:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696760, encodeId=35001696e6071, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 03 18:07:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608010, encodeId=fa1f1608010d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 05 02:07:00 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-01-03 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804499, encodeId=b980180449999, content=<a href='/topic/show?id=6484e7286bb' target=_blank style='color:#2F92EE;'>#纤维血管生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77286, encryptionId=6484e7286bb, topicName=纤维血管生长)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed May 23 08:07:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914184, encodeId=b7791914184f0, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Sep 27 11:07:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796683, encodeId=eeee1e9668332, content=<a href='/topic/show?id=e08d182e056' target=_blank style='color:#2F92EE;'>#valve#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18270, encryptionId=e08d182e056, topicName=valve)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Thu May 24 11:07:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696760, encodeId=35001696e6071, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Wed Jan 03 18:07:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608010, encodeId=fa1f1608010d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 05 02:07:00 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map